The newly launched system is intended to reduce time to hemostasis and ambulation after diagnostic or interventional procedures, the Dublin, Ohio-based company said. The system also includes a next-generation deployment system designed to improve predictable deployment.
“The notion of secure extravascular closure with nothing left behind is very appealing for a number of reasons. In addition to the clinical benefits of undisrupted flow in the artery, Mynx Control VCD minimizes technique-related issues and emphasizes simplicity and reproducibility,” Cordis global medical director Dr. Ali Almedhychy said in a prepared statement.
Cordis said that the Mynx Control system also features a sheath catch that is compatible with procedural sheaths, a tension indicator for improved device positioning and sealant deployment and a simplified, ergonomic handle.
The system uses a dual-mode active sealing mechanism that contours to the arterial wall and expands to fill the tissue tract, creating a matrix structure for clot formation, Cordis said. The components are made to be resorbed within 30 days.
“Mynx Control VCD reinforces Cordis leadership in global vascular closure innovation. By adding new access, diagnostic, interventional and closure products to our portfolio, we continue to make significant patient-centric contributions to the delivery of healthcare,” Cordis prez Patrick Holt said in a press release.
In May, Cordis won a date with an FDA panel looking to discuss the premarket approval application for its InCraft AAA stent graft system designed for treating infrarenal abdominal aortic aneurysms.